Nanotherapeutics to overcome conventional cancer chemotherapy limitations

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 1, 2011, Pages 67-77

  Moorthi, C ^a   Manavalan, R ^a   Kathiresan, K ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CAMPTOTHECIN; CHITOSAN; CURCUMIN; CYCLODEXTRIN; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; MACROGOL; MAGNETIC NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; NANOCRYSTAL; NANOPARTICLE; PACLITAXEL; POLOXAMER; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; POLYPROPYLENE OXIDE; SELENIUM DERIVATIVE; SOLID LIPID NANOPARTICLE; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; [1,2 [BIS[1,2 BENZISOSELENAZOL 3 (2H) ONE]]ETHANE];

CANCER CELL; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CELL DAMAGE; CELL PROLIFERATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TARGETING; HUMAN; MICELLIZATION; MULTIDRUG RESISTANCE; NANOTHERAPY; NEOPLASM; NONHUMAN; REVIEW; TARGET CELL; THERAPY;

EID: 79951806556     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j30c7d     Document Type: Review

References (91)

1. Nandakumar A. National Cancer Registry Programme, Indian Council of Medical Research, Consolidated report of the population based cancer registries, New Delhi, India: 1990-96.
2. Dinshaw KA, Rao DN, Ganesh B. Tata Memorial Hospital Cancer Registry Annual Report, Mumbai, India, 1999.
3. Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu, Michael J Thun. Cancer Statistics, 2009. CA Cancer J Clin, 2009; 59:225-249.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin, 2010; 60(5):277-300.
5. Li C. Poly (L-glutamic acid) - anticancer drug conjugates. Adv Drug Deliv Rev, 2002; 54: 695-713.
6. Rang, H.P, Dale, M.M, Ritter, J.M, Flower R. Rang and Dale's Pharmacology, 6th edition. Edinburgh, UK Churchill Livingstone, 2007.
7. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst, 2003; 20:357-403.
8. Luo Y, Prestwich GD. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets, 2002; 2:209-226.
9. Simon Benita. Microencapsulation Methods and Industrial Applications. 2nd edn. Informa Healthcare, London, pp 625-671, 2006.
10. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc), 2000; 65:95-106.
11. Kinam Park. Nanotechnology: What it can do for drug delivery J Control Release, 2007; 120(1-2):1-3.
12. Svetlana Gelperina. The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2005; 172:1487-1490.
13. Kwangjae Cho, Xu Wang, Shuming Nie, Zhuo (Georgia) Chen, and Dong M. Shin. Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin Cancer Res, 2008; 14(5):1310-1316.
14. Mohanraj VJ, Chen Y. Nanoparticles - A Review. Tropical Journal of Pharmaceutical Research, 2006; 5 (1): 561-573.
15. Xu Wang, Yiqing Wang, Zhuo (Georgia) Chen, Dong M. Shin. Advances of Cancer Therapy by Nanotechnology. Cancer Res Treat, 2009; 41(1):1-11.
16. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today, 2003; 8:396.
17. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin, 2008; 58:97-110.
18. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. American Journal of Pathology, 1988; 133:95-109.
19. Hiroya Hashizume, Peter Baluk, Shunichi Morikawa, John W. McLean, Gavin Thurston, Sylvie Roberge, Rakesh K. Jain and Donald M. McDonald. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol, 2000; 156:1363-1380.
20. Jain RK. Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function. J Control Release, 2001; 74(1-3):7-25.
21. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev, 1987; 6:559-593.
22. Brannon Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 2004; 56:1649-1659.
23. Jaspreet K. Vasir, Maram K. Reddy, Vinod D. Labhasetwar. Nanosystems in Drug Targeting: Opportunities and Challenges. Current Nanoscience, 2005; 1:47-64.
24. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science, 2004; 303:1818-1822.
25. Nathanson SD, Nelson L. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann Surg Oncol, 1994; 1:333.
26. Kalevi Kairemo, Paola Erba, Kim Bergström, Ernest KJ. Pauwels. Nanoparticles in Cancer. Current Radiopharmaceuticals, 2008; 1:30-36.
27. Lavasanifar A, Samuel J, Kwon GS. Poly (ethylene oxide)-block-poly (L-amino acid) micelles for drug delivery. Advanced Drug Delivery Reviews, 2002; 54(2):169-190.
28. Van Vlerken L, Vyas T, Amiji M. Poly (ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery. Pharmaceutical research, 2007; 24(8):1405-1414.
29. Emily Gullotti, Yoon Yeo. Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery. Mol. Pharmaceutics, 2009, 6 (4):1041-1051.
30. Lammers T, Hennink WE, Storm G. Tumortargeted nanomedicines: principles and practice. Br J Cancer, 2008; 99(3):392-397.
31. Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci, 2006; 11:506-519.
32. Elwood PC. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem, 1989; 264:14893-14901.
33. Giuseppe Destito, Robert Yeh, Chris S. Rae, Finn MG, Marianne Manchester. Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol, 2007; 14(10):1152-1162.
34. Guangya Xiang, Jun Wu, Yanhui Lu, Zhilan Liu, Robert J. Lee. Synthesis and Evaluation of a Novel Ligand for Folate-mediated Targeting liposomes. Int J Pharm, 2008; 356(1-2):29-36.
35. Zhaowu Zhang, Jing Jia, Youqun Lai, Yanyan Ma, Jian Weng, Liping Sun Conjugating folic acid to gold nanoparticles through glutathione for targeting and detecting cancer cells. Bioorganic & Medicinal Chemistry, 2010; 18(15):5528-5534.
36. Fabiana Canal, María J. Vicent, Gianfranco Pasut, Oddone Schiavon (2010) Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates. Journal of Controlled Release, 2010; 146 (3):388-399.
37. Zhang C, Zhao L, Dong Y, Zhang X, Lin J, Chen Z. Folate-mediated poly (3-hydroxybutyrate-co-3- hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur J Pharm Biopharm, 2010; 76(1):10-16.
38. Xiaobin B. Zhao, Robert J. Lee. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Advanced Drug Delivery Reviews, 2004; 56(8):1193-1204.
39. Milla M Hänninen, Joonas Haapasalo, Hannu Haapasalo, Robert E Fleming, Robert S Britton, Bruce R Bacon, Seppo Parkkila. Expression of iron-related genes in human brain and brain tumors. BMC Neurosci, 2009; 10:36.
40. Jiang Chang, Youssef Jallouli, Maya Kroubi, Xubo Yuan, Wei Feng, Chun-sheng Kang, Pei-yu Pu, Didier Betbeder. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. International Journal of Pharmaceutics, 2009; 379 (2):285-292.
41. Tracy R. Daniels, Tracie Delgado, Gustavo Helguera, Manuel L. Penichet. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clinical Immunology, 2006; 121(2):159-176.
42. Yu Zheng, Bo Yu, Wanlop Weecharangsan, Lngzhu Piao, Michael Darby, Yicheng Mao, Rumiana Koynova, Xiaojuan Yang, Hong Li, Songlin Xu, L. James Lee, Yasuro Sugimoto, Robert W. Brueggemeier, Robert J. Lee. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7a-APTADD to breast cancer cells. International Journal of Pharmaceutics, 2010; 390 (2):234-241.
43. Rohit S. Mulik, Jukka Mönkkönen, Risto O. Juvonen, Kakasaheb. R. Mahadik, Anant R. Paradkar. Transferrin Mediated Solid Lipid Nanoparticles Containing Curcumin: Enhanced In Vitro Anticancer Activity By Induction of Apoptosis. International Journal of Pharmaceutics, 2010; 398 (1-2):190-203.
44. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc), 2000; 65:95-106.
45. Dean M, Hamon Y, Chimini G. The human ATPbinding cassette (ABC) transporter superfamily. J Lipid Res, 2001; 42:1007-1017.
46. Efferth T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med, 2001;1:45-65.
47. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 1992; 258:1650-1654.
48. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res, 1999; 59:4559-4563.
49. Gupta PK. Drug targeting in cancer chemotherapy: a clinical perspective. J Pharm Sci, 1990; 79:949-962.
50. Zee-Cheng RKY, Cheng CC. Delivery of anticancer drugs. Methods Find Exp Clin Pharmacol, 1989; 11:439-529.
51. Belhoussine R, Morjani H, Millot JM, Sharonov S, Manfait M. Confocal scanning microspectrofluorometry reveals specific anthracycline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells. J Histochem Cytochem, 1998; 46:1369-1376.
52. Simon SM. Role of organelle pH in tumor cell biology and drug resistance. Drug Discovery Today, 1999; 4:32-38.
53. Xiang Rong Song, Zheng Cai, Yu Zheng, Gu He, Feng Yu Cui, Dao Qiong Gong, Shi Xiang Hou, Si Jing Xiong, Xiang Jie Lei, Yu Quan Wei. Reversion of multidrug resistance by coencapsulation of vincristine and verapamil in PLGA nanoparticles. European Journal of Pharmaceutical Sciences, 2009; 37(3-4):300-305.
54. Yanagisawa, Tsuneo; Shimizu, Toshio; Kuroda, Kazuyuki; Kato, Chuzo. The preparation of alkyltrimethylammonium-kanemite complexes and their conversion to microporous materials. Bulletin of the Chemical Society of Japan, 1990; 63:988.
55. Beck JS, Vartuli JC, Roth WJ, Leonowicz ME, Kresge CT. A New Family of Mesoporous Molecular Sieves Prepared with Liquid Crystal Templates. American Chemical Society, 1992; 114 (27):10834-10843.
56. Brian G. Trewyn, Igor I. Slowing, Supratim Giri, Hung-Ting Chen, Victor SY. Lin. Synthesis and Functionalization of a Mesoporous Silica Nanoparticle Based on the Sol-Gel Process and Applications in Controlled Release. Accounts of Chemical Research, 2007; 40(40):846-853.
57. Dongyuan Zhao, Jianglin Feng, Qisheng Huo, Nicholas Melosh, Glenn H. Fredrickson, Bradley F. Chmelka, Galen D. Stucky. Triblock Copolymer Syntheses of Mesoporous Silica with Periodic 50 to 300 Angstrom Pores. Science, 1998; 279(5350):548-552.
58. Alex M. Chen, Min Zhang, Dongguang Wei, Dirk Stueber, Oleh Taratula, Tamara Minko, Huixin He. Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug Resistant Cancer Cells. Small, 2009; 5(23):2673-2677.
59. Melike Üner and Gülgün Yener. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine, 2007; 2(3):289-300.
60. Keon Wook Kang, Myung-Kwan Chun, Ok Kim, Robhash Kusam Subedi, Sang-Gun Ahn, Jung- Hoon Yoon, Hoo-Kyun Choi. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine Nanotechnology Biology and Medicine, 2010; 6(2):210-213.
61. Lam W, Leung CH, Chan HL, and Fong WF Toxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells: optimization of dextran size. Anticancer Drugs, 2000; 11: 377-384.
62. Yang Liu, Leaf Huang and Feng Liu. Paclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer Mol Pharmaceutics, 2010; 7(3):863-869.
63. Santander-Ortega MJ, Jódar-Reyes AB, Csabac N, Bastos-González D, Ortega-Vinuesa JL. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms. Journal of Colloid and Interface Science, 2006; 302:522-529.
64. Amit K. Sharma, Li Zhang, Shu Li, David L. Kelly, Valery Yu. Alakhov, Elena V. Batrakova, Alexander V. Kabanov. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. Journal of Controlled Release, 2008; 131 (3):220-227.
65. Daria Yu. Alakhova, Nataliya Y. Rapoport, Elena V. Batrakova, Alexander A. Timoshin, Shu Li, David Nicholls, Valery Yu. Alakhov, Alexander V. Kabanov. Differential metabolic responses to pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancers. Journal of Controlled Release, 2010; 142(1):89-100.
66. Yangqing Zhang, Lina Tang, Leilei Sun, Junbo Bao, Cunxian Song, Laiqiang Huang, Kexin Liu, Yan Tian, Ge Tian, Zhen Li, Hongfan Sun, Lin Mei. A novel paclitaxel-loaded poly (e- caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomaterialia, 2010; 6(6):2045-2052.
67. Bao-an Chen, Bin-bin Lai, Jian Cheng, Guo-hua Xia, Feng Gao, Wen-lin Xu, Jia-hua Ding, Chong Gao, Xin-chen Sun, Cui-rong Xu, Wen-ji Chen, Ning-na Chen, Li-jie Liu, Xiao-mao Li, Xue-mei Wang. Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. International journal of nanomedicine, 2009; 4:201-208.
68. Katherine Bowman and Kam W Leong. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine, 2006; 1(2):117-128.
69. Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med, 2008; 59:251-265.
70. Langer R. Drug delivery and targeting. Nature, 1998; 392:5-10.
71. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol, 2003; 24:253-262.
72. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet, 2003; 42:665-685.
73. Bushrab NF, Müller RH. Nanocrystals of poorly soluble drugs for oral administration. J New Drugs, 2003; 5:20-22.
74. Jens-Uwe A H Junghanns Rainer H Müller. Nanocrystal technology, drug delivery and clinical applications. International Journal of Nanomedicine, 2008; 3(3):295-309.
75. Feng Liu, Ji-Young Park, Yong Zhang, Christine Conwell, Yang Liu, Surendar Reddy Bathula, Leaf Huang. Targeted cancer therapy with novel high drug-loading nanocrystals. Journal of Pharmaceutical Sciences, 2010; 99(8):3542-3551.
76. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther, 2007; 7(7):919-943.
77. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev, 2008; 60:876-885.
78. Purcell M, Neault JF, Tajmir-Riahi HA. Interaction of Taxol with human serum albumin. Biochim Biophys Acta, 2000; 1478:61-68.
79. Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem, 2001; 268:2187-2191.
80. Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Federica Tomao, Silverio Tomao. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine, 2009; 4:99-105.
81. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI- 007, compared with Cremophor-based paclitaxel. Clin Cancer Res, 2006; 12(4):1317-1324.
82. MaryAnn Foote. Using nanotechnology to improve the characteristics of antineoplastic drugs: Improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnology Annual Review, 2007; 13:345-357.
83. Felix Kratz. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. Journal of Controlled Release, 2008; 132(3):171-183.
84. Franco Dosio, Paola Brusa, Paola Crosasso, Silvia Arpicco, Luigi Cattel. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. Journal of Controlled Release, 1997; 47(3):293-304.
85. Maria Laura Immordino, Franco Dosio, and Luigi Cattel, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int J Nanomedicine, 2006; 1(3):297-315.
86. Allen Zhang J, Gopal Anyarambhatla, Lan Ma, Sydney Ugwu, Tong Xuan, Tommaso Sardone, Imran Ahmad, Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. European Journal of Pharmaceutics and Biopharmaceutics, 2005; 59(1):177-187.
87. Xinru Li, Zhuoli Yang, Kewei Yang, Yanxia Zhou, Xingwei Chen, Yanhui Zhang, Fei Wang, Yan Liu, and Lijun Ren. Self-Assembled Polymeric Micellar Nanoparticles as Nanocarriers for Poorly Soluble Anticancer Drug Ethaselen. Nanoscale Res Let, 2009; 4(12):1502-1511.
88. Thorsteinn Loftsson, Dominique Duchene. Cyclodextrins and their pharmaceutical application. International Journal of Pharmaceutics, 2007; 329:1-11.
89. Yu Liu, Guo-Song Chen, Yong Chen, Dong-Xu Cao, Zhi-Qiang Ge, Ying-Jin Yuan. Inclusion complexes of paclitaxel and oligo (ethylenediamino) bridged bis(ß-cyclodextrin)s: solubilization and antitumor activity. Bioorganic & Medicinal Chemistry, 2004; 12 (22):5767-5775.
90. Agüeros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly (anhydride) nanoparticles. Journal of Controlled Release, 2010; 145(1):2-8.
91. Can Zhang, Ya Ding, Liangli (Lucy) Yu, Qineng Ping. Polymeric micelle systems of hydroxycamptothecin based on amphiphilic Nalkyl- N-trimethyl chitosan derivatives. Colloids and Surfaces B: Biointerfaces, 2007; 55(2):192-199.